MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/falgy.2026.1940709

Медицинская библиотека · Frontiers in allergy · 2026

Sublingual allergen immunotherapy: evidence from randomized trials, real-world studies and meta-analyses.

Paoletti Giovanni, Valli Nicolò, Di Bona Danilo, Costanzo Giulia Anna Maria Luigia, Ledda Andrea Giovanni, Del Giacco Stefano, Giovannini Mattia, Catamerò Francesco, Mori Francesca, Guida Giuseppe, Ricciardolo Fabio Luigi Massimo, Bertolini Francesca, Poto Remo, Pelaia Corrado, Varricchi Gilda, Canonica Giorgio Walter, Heffler Enrico

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND

Allergen immunotherapy is the only potentially disease-modifying treatment for IgE-mediated respiratory allergy. Among the available routes, sublingual immunotherapy (SLIT) has gained prominence because of its favorable safety profile and greater patient acceptability.

OBJECTIVES

This narrative review critically appraises the clinical efficacy, real-world effectiveness, and long-term disease-modifying potential of SLIT for seasonal and perennial respiratory allergies by integrating evidence from randomized controlled trials, large observational cohorts, and meta-analyses, with attention to allergen- and product-specific outcomes and age-related differences.

RESULTS

Robust RCT evidence supports clinically meaningful reductions in symptoms and medication use with grass and HDM SLIT tablets, with sustained benefits observed up to 1-2 years after a 3-year treatment course in key trials. Real-world cohorts corroborate these findings and additionally report a reduced risk of new asthma onset and lower long-term medication dispensing after SLIT. Evidence for SLIT in asthma shows reductions in exacerbation risk in some trials, although its effects on day-to-day control are less consistent. Pediatric trials generally mirror adult outcomes, with favorable safety and efficacy, particularly for standardized tablets; however, heterogeneity across trials and historical methodological limitations remain important caveats. Meta-analyses confirm overall efficacy but highlight substantial between-study heterogeneity and the importance of product-specific evaluations.

CONCLUSIONS

SLIT could be an effective, well-tolerated, disease-modifying option for respiratory allergic rhinitis and shows promise for selected asthma outcomes. Optimal benefits require standardized, adequately dosed formulations and sustained adherence (≥3 years). Future research should prioritize product-specific, adequately powered trials with standardized outcomes to refine patient selection and long-term disease-modification endpoints.

Для цитирования: Paoletti Giovanni, Valli Nicolò, Di Bona Danilo, Costanzo Giulia Anna Maria Luigia, Ledda Andrea Giovanni, Del Giacco Stefano, Giovannini Mattia, Catamerò Francesco, Mori Francesca, Guida Giuseppe, Ricciardolo Fabio Luigi Massimo, Bertolini Francesca, Poto Remo, Pelaia Corrado, Varricchi Gilda, Canonica Giorgio Walter, Heffler Enrico. Sublingual allergen immunotherapy: evidence from randomized trials, real-world studies and meta-analyses.. Frontiers in allergy. 2026. DOI: 10.3389/falgy.2026.1940709.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.